Work

Phase I Trial of Irreversible Pan-Erbb Inhibitor Dacomitinib (DAC) in Combination with ALK/MET Inhibitor Crizotinib (CRIZ) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

Year: 2012

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(20)33887-4

Authors: P.A. Janne, A.T. Shaw, G. Giaccone, D.R. Camidge, S.M. Shreeve, Z. Goldberg, Y. Tang, B. Solomon

Institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital, National Cancer Institute, University of Colorado Cancer Center, Pfizer (United States), Peter MacCallum Cancer Centre

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2999016555

FWCI: 2.134

Cites:

Cited by: 10

Related to: 10